Recently, we identified the promising anticancer potential of the synthetic\n4-thiazolidinone-based anticancer lead compound Les-3833 which demonstrated tumor-suppressing\naction in vitro and in vivo. Based on the results of previous studies, the aim of this research was\nto investigate the cytotoxicity in vitro and the biodistribution in laboratory mice to support the\nbiotherapeutic drug development of Les-3833. Les-3833 (2.5 mg/kg) was intravenously injected into\nmale Balb/c mice. Measurements were performed at 5 min, 15 min, 1 h, 4 h, and 24 h time points\nin blood plasma, brain, liver, and kidney using high-performance liquid chromatography/tandem\nmass spectrometry. After the administration of Les-3833, the maximum level of this compound\nwas observed in plasma at 2.08 min. In the brain, the mean maximum concentration of Les-3833\nwas 7.17 ng/mL at 5 min, while after 15 min, it was not found. In the liver, at 5 min, the maximum\nconcentration was 1190 ng/g. At 15 min, concentration of Les-3833 in the liver decreased by 14.3%;\nat 6 h by 22.8%; and after 24 h by 64.7%. Its maximum concentration in kidney was 404 ng/g within\n5â??15 min, at 1 h it decreased by 36.1%, and after 24 h by 49.3%. Thus, Les-3833 was rapidly taken\nup by different organs from the bloodstream, partially metabolized in the liver, and excreted mainly\nthrough the kidneys, while in the brain, a very low concentration could be observed for only a short\nperiod of time.
Loading....